Sutton Council is to present plans for the London Cancer Hub – a proposed new global centre for cancer research and treatment in south London – to borough councillors.

The council is seeking approval for the London Cancer Hub Development Framework at the Housing, Economy and Business Committee on Tuesday 27 September.

The Development Framework sets out proposals for the London Cancer Hub. The vision is to create a world-leading life-science campus specialising in cancer research, treatment, education and enterprise. It will be located on the Sutton site of The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust in Belmont.

cancer_origThe London Cancer Hub will be a partnership between the London Borough of Sutton and the Institute for Cancer Research (ICR), with supporting partners The Royal Marsden, the Greater London Authority and the Epsom and St Helier University Hospitals NHS Trust.

The total transformation of the site will see inward investment in excess of £1bn over the lifetime of the project. The London Cancer Hub is expected to create more than 13,000 new jobs in Sutton – 7,000 life-science, clinical and support staff, and another 6,200 in the site’s construction. It will be, offering research and development space for biotech, pharma and software companies, and equipment manufacturers.

Sutton Council also plans to build a new free school on the site, providing secondary education for up to 1,275 students and benefitting from being part of the life science campus.

It is hoped the London Cancer Hub will also be an opportunity to bring further public transport investment into the borough through the creation of an integrated transport system extending the Tramlink from Wimbledon to Sutton Station via Morden and onwards to the Belmont site.

The London Cancer Hub will form one of three outstanding life-science districts within London. As such, it will be one of the most significant regeneration projects in London and will require the co-ordinated efforts of public institutions and private partners.